(NASDAQ: SNGX) Soligenix's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 67.39%.
Soligenix's earnings in 2026 is -$10,954,077.On average, 4 Wall Street analysts forecast SNGX's earnings for 2026 to be -$13,230,575, with the lowest SNGX earnings forecast at -$13,074,921, and the highest SNGX earnings forecast at -$13,230,575. On average, 4 Wall Street analysts forecast SNGX's earnings for 2027 to be -$11,491,700, with the lowest SNGX earnings forecast at -$12,348,537, and the highest SNGX earnings forecast at -$10,428,806.
In 2028, SNGX is forecast to generate -$10,886,873 in earnings, with the lowest earnings forecast at -$10,459,937 and the highest earnings forecast at -$11,207,076.